{"disease":{"id":"stage-4-nsclc","name":"stage 4 nsclc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07365319","title":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Eikon Therapeutics","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT06262321","title":"Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT05891197","title":"A Biomarker Screening Protocol for Participants With Solid Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}